glp 1 and graves disease Glucagon-like peptide receptor agonist use risk of thyroid cancer: Scandinavian cohort study Dual Glucagon-Like Peptide-1 (GLP-1) and

However, emerging research suggests that these medications may offer unexpected benefits for brain health, including improvements in addiction, depression, and cognitive function

The Australia GLP-1 receptor agonist market size was valued at USD 570.49 million in 2025 and is expected to hit around USD 2,117.46 million by 2035, growing at a CAGR of 14.01% from 2026 to 2035.

As a clinician, its critical we counsel patients not only on the metabolic benefits, but also the oral health implications of these therapies

So far, however, it has been injectables leading the way to approval.

You can find budget-friendly options for weight loss injections at Everglow Medical Spa.